Irritable Bowel Syndrome (IBS): Diagnosis and Management
Written by Dr. Muhammad Salar Raza · Manually reviewed by Dr. Muhammad Salar Raza · Content updated
Clinical Pathway
Irritable Bowel Syndrome (IBS) is a common, chronic functional gastrointestinal disorder characterized by recurrent abdominal pain associated with altered bowel habits, without any identifiable structural or biochemical abnormalities. Management involves a combination of dietary modifications, lifestyle changes, and pharmacotherapy tailored to the predominant symptoms. Dietary approaches like the low-FODMAP diet, stress management techniques, and regular exercise are often recommended. Medications include antispasmodics for pain, laxatives for constipation, anti-diarrheals, and sometimes low-dose tricyclic antidepressants or selective serotonin reuptake inhibitors to modulate pain and gut function. Psychological therapies such as cognitive behavioral therapy (CBT) are also effective. Key symptoms include recurrent abdominal pain, often cramping, which is related to defecation or a change in stool frequency or form. Patients experience altered bowel habits, presenting as predominant diarrhea (IBS-D), constipation (IBS-C), or a mixed pattern (IBS-M). Other common symptoms include bloating, gas, abdominal distension, and a sense of incomplete evacuation.
Clinical Reasoning
IBS is a multifactorial disorder involving altered gut motility, visceral hypersensitivity, and dysfunction of the brain-gut axis. Contributing factors include dysregulation of the gut microbiome, post-infectious inflammation, and psychological stressors, which collectively lead to increased gut permeability and immune activation. There are no structural changes in the bowel; rather, it's a functional disturbance in the communication between the gut and the brain. IBS is a chronic condition with a fluctuating course, characterized by periods of symptom exacerbation and remission. While it significantly impacts quality of life, it does not lead to serious organic diseases, increase the risk of inflammatory bowel disease, or predispose to colorectal cancer. With appropriate management, most individuals can achieve significant symptom control and maintain a good quality of life. Female sex,Younger age (typically under 50),History of gastroenteritis (post-infectious IBS),Family history of IBS,Presence of psychological stressors, anxiety, or depression,History of stressful or traumatic life events
Sample MCQ
A 45-year-old female with severe diarrhea-predominant irritable bowel syndrome (IBS-D) reports persistent abdominal pain, bloating, and urgent bowel movements despite trials of dietary modifications, loperamide, and dicyclomine. Her physician plans to initiate a 5-HT3 receptor antagonist approved for refractory IBS-D in women to decrease visceral hypersensitivity and colonic motility. Which medication is the most appropriate choice?
- ADiphenoxylate
- BDicyclomine
- CLoperamide
- DAlosetron
Correct Answer: D
### TLDR The patient's presentation of severe, refractory IBS-D in a woman, requiring a 5-HT3 receptor antagonist to reduce visceral hypersensitivity and colonic motility, points directly to **Alosetron**. This drug is specifically indicated for such cases after conventional therapies have failed. ### Comparison Table | Option | Mechanism | Clinical Nuance | Key Distinction | | :------- | :-------------------------------- | :------------------------------ | :---------------------------------- | | Diphenoxylate | Opioid agonist; slows gut motility. | Diarrhea treatment, often with atropine. | Opioid, abuse potential, not 5-HT3. | | Dicyclomine | Anticholinergic, antispasmodic. | Reduces abdominal pain/spasms in IBS. | Smooth muscle relaxant, not 5-HT3. | | Loperamide | Peripheral mu-opioid agonist; slows gut. | Symptomatic relief for diarrhea. | Conventional anti-diarrheal, not 5-HT3. | | **Alosetron** | 5-HT3 receptor antagonist. | Severe IBS-D in women, refractory cases. | Specific 5-HT3 action, targets visceral pain. | ### Detailed Breakdown The question describes a 45-year-old female with severe diarrhea-predominant irritable bowel syndrome (IBS-D) that has been refractory to conventional treatments like dietary modifications, loperamide, and dicyclomine. The key to identifying the correct drug lies in its specified mechanism of action: a 5-hydroxytryptamine-3 (5-HT3) receptor antagonist, specifically approved for women with severe IBS-D who have not responded to conventional therapy, to reduce visceral hypersensitivity and colonic motility. **Alosetron** is precisely this drug. It is a selective 5-HT3 receptor antagonist that reduces visceral pain sensation, slows colonic transit time, and decreases colonic motility, which are beneficial effects in IBS-D. Due to its potential for serious adverse effects, including ischemic colitis, its use is restricted to women with severe IBS-D who have not responded to conventional therapy and meet specific criteria. This perfectly aligns with the clinical scenario presented. Let's look at why the other options are incorrect: * **Diphenoxylate** is an opioid agonist that reduces gut motility. It is used for diarrhea but is not a 5-HT3 antagonist and is not specifically indicated for severe refractory IBS-D with the described mechanism of action. It also has a potential for abuse, often formulated with atropine. * **Dicyclomine** is an anticholinergic and antispasmodic agent used to relieve abdominal pain and cramping in IBS. The patient in the scenario has already failed a trial of dicyclomine, and it is not a 5-HT3 antagonist. * **Loperamide** is a peripheral mu-opioid receptor agonist that slows intestinal motility and reduces fluid and electrolyte loss. It is a common over-the-counter medication for diarrhea but is not a 5-HT3 antagonist. Moreover, the patient has already failed loperamide treatment, indicating a need for a different mechanism of action. Therefore, given the specific mechanism of action (5-HT3 receptor antagonist) and the indication (severe, refractory IBS-D in women), **Alosetron** is the only correct answer.
Guidelines and further reading
Related Clinical Topics
Gastroesophageal Reflux Disease (GERD): Diagnosis and Management
Gastroesophageal Reflux Disease (GERD) is a chronic digestive condition characterized by the backward flow of stomach acid or bile into the esophagus, causing irritation and inflammation. This reflux occurs when the lower esophageal sphincter (LES) weakens or relaxes inappropriately, failing to prevent gastric contents from returning to the food pipe. Treatment typically begins with lifestyle modifications such as dietary changes (avoiding trigger foods), weight loss, and elevating the head of the bed. Pharmacological interventions include antacids for immediate relief, H2-receptor blockers to reduce acid production, and proton pump inhibitors (PPIs) as the most effective agents for sustained acid suppression and healing. For severe or refractory cases, surgical options like fundoplication may be considered to reinforce the lower esophageal sphincter. The hallmark symptom is heartburn, a burning sensation in the chest that often worsens after eating, at night, or when lying down. Other common symptoms include regurgitation of food or sour liquid, chest pain, dysphagia (difficulty swallowing), chronic cough, hoarseness, and feeling a lump in the throat (globus sensation). Less common symptoms can include nausea, bad breath, or dental erosion.
Acute Pancreatitis: Diagnosis and Management
Diagnose acute pancreatitis with two of three criteria: typical epigastric pain radiating to the back, lipase or amylase at least three times the upper limit of normal, and characteristic imaging. Assess severity and hydration, then begin early, goal-directed isotonic crystalloid therapy with frequent reassessment, with adequate analgesia and antiemetics. Start enteral feeding as soon as tolerated, favouring oral or nasojejunal routes over parenteral nutrition. Identify the cause: gallstones and alcohol dominate, so obtain liver tests and a right upper quadrant ultrasound. Urgent ERCP is indicated only for cholangitis or progressive biliary obstruction. Monitor for necrosis, fluid collections, respiratory failure, and organ dysfunction, escalating to high-dependency care when severe.
SMLE Preparation Resources
Master the 2026 SMLE
Explore more clinical protocols in the SMLEREVISE Clinical Knowledge Library.
Try the QBank & Scaled Mocks